Evansville Runner Bob Wolf Passes Away from Brain CancerNOVEMBER 8TH, 2018 MITCH ANGLE EVANSVILLE, INDIANAThe Evansville running community is mourning after the loss of an area legend.Bob Wolf passed away following a lengthy battle with brain cancer on the morning of November 8th.Wolf was one of the first members of Team 13, a group of runners who train together for the Evansville Half Marathon.When he was diagnosed with brain cancer earlier this year, Wolf made a goal to take part in his 15th Half Marathon. He was able to do so with help from family and friends who call themselves the “Wolf Pack.” They started a Go Fund Me page to raise enough money to buy a racing wheelchair and met their goal within just three weeks.Wolf took part in his final Half Marathon last month with the help of his Wolf Pack.A date for his funeral has not been set.Previous stories on Wolf’s journey since his diagnoses can be seen below:Man With Brain Cancer To Complete 15th Evansville Half MarathonRunner Diagnosed With Cancer Holds Nothing Back For 8KCancer Survivor’s Fundraising Campaign Donating To Chemo Buddies FacebookTwitterCopy LinkEmail
As the temperature drops in Boston, the Harvard Ed Portal is partnering with Action for Boston Community Development (ABCD) on a winter coat drive to benefit residents and community members in the area.The drive is collecting new and gently worn winter coats and clothing for all ages through Dec. 11. Dropoffs will be collected at 224 Western Ave. in Allston.Elaina Schreckenberger, operations manager at the ABCD Neighborhood Opportunity Center in Allston-Brighton, took part in the drive for the first time last year. The turnout was encouraging and included items from infants’ sizes up to men’s XXL, she said.“This year, I think we would like to hope for a similar collection, if not more, with so many people in need of assistance since being unemployed,” Schreckenberger added.All cold-weather items — including hats, scarves, mittens, gloves, and ear warmers — are welcome.For more information, visit ABCD’s website.
The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, US health officials said Monday, raising hopes in the global fight against the disease.But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe.The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts. Global race Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines to the new coronavirus.An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.But only randomized trials allow scientists to know for sure whether it really helps or whether patients would have recovered without it.Another US pharma called Inovio, which is creating a DNA-based vaccine, has said it will enter clinical trials next month. Regeneron is trying to isolate coronavirus-fighting antibodies that can be administered intravenously to confer temporary immunity, and hopes to start human trials by summer.According to the World Health Organization, 80 percent of COVID-19 cases are mild, 14 percent are severe and about five percent result are critical, resulting in severe respiratory illness that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.Patients with mild cases recover in a week or two while severe cases can take six or more weeks.Recent estimates suggest about one percent of all infected people die. Topics : “Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats.”This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever.Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry.The Moderna candidate vaccine carries the genetic information of this spike in a substance called “messenger RNA.”Injecting human tissue with the spike’s messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus. “The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the NIH said. “The first participant received the investigational vaccine today.”Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI).There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December.It has claimed 7,000 deaths, according to an AFP tally, most in China followed by Italy.